Wholehealth Products, Inc. (GWPC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Wholehealth Products, Inc. (GWPC) trades at $0.00 with AI Score 46/100 (Grade C). Wholehealth Products, Inc. develops, manufactures, and markets in vitro diagnostic tests for over-the-counter (OTC) and point-of-care use in the United States. Market cap: $51,950, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for GWPC: GWPC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GWPC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GWPC: the 1 perspectives are evenly split.
How is this calculated? →Wholehealth Products, Inc. (GWPC) Healthcare & Pipeline Overview
Wholehealth Products, Inc. focuses on developing, manufacturing, and marketing in vitro diagnostic tests for OTC and point-of-care markets in the U.S. The company provides diagnostic test kits for consumer and professional use, operating in a competitive healthcare landscape with a small employee base and OTC market focus.
What Is the Investment Thesis for GWPC?
Wholehealth Products, Inc. operates in the niche market of OTC and point-of-care in vitro diagnostic tests. The company's small size, with only four employees, presents both opportunities and challenges. Key value drivers include expanding its product line of diagnostic test kits and increasing market penetration in the U.S. healthcare sector. Growth catalysts involve securing partnerships with major retailers for OTC sales and expanding distribution networks to reach more healthcare facilities. However, potential risks include intense competition from larger players in the diagnostics market and the need for continuous innovation to maintain a competitive edge. The company's beta of -3084.77 indicates high volatility relative to the market.
Based on FMP financials and quantitative analysis
GWPC Key Highlights
- Focus on in vitro diagnostic tests for OTC and point-of-care markets.
- Serves both consumer and healthcare professional segments.
- Operates primarily within the United States.
- Small employee base of 4 individuals.
- Formerly known as Gulf Western Petroleum Corporation, indicating a significant business transformation.
Who Are GWPC's Competitors?
GWPC is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SI SHOULDER INNOVATIONS, INC. | $21.14 | -0.61% | $438.41M | 59 |
| TRXDW TransEnterix, Inc. | $0.15 | -11.76% | $40.09M | 53 |
| ACIXF Acarix AB (publ) | $0.03 | -3.57% | $31.28M | 52 |
| BMXXY bioMérieux S.A. | $7.53 | -6.98% | $8.88B | 46 |
| EBRCZ EBR Systems, Inc. | $0.31 | +0.00% | $194.77M | 45 |
| EBOSY EBOS Group Limited | $24.13 | -7.19% | $1.24B | 42 |
| AVNBF Avon Technologies Plc | $21.28 | -5.37% | $626.73M | 38 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GWPC's Key Strengths?
- Focus on niche market of OTC and point-of-care diagnostic tests.
- Established presence in the U.S. market.
- Proprietary diagnostic test kit formulations.
- Serves both consumer and professional healthcare segments.
What Are GWPC's Weaknesses?
- Small employee base limits operational capacity.
- Limited financial resources compared to larger competitors.
- Dependence on a limited product line.
- OTC Other tier listing indicates higher risk and lower liquidity.
What Could Drive GWPC Stock Higher?
- Potential partnerships with major retailers to expand OTC product distribution.
- Development and launch of new diagnostic test kits for common ailments.
- Increasing demand for point-of-care diagnostic solutions in medical clinics and hospitals.
What Are the Key Risks for GWPC?
- Intense competition from larger diagnostic companies with greater resources.
- Evolving regulatory landscape for diagnostic tests may require significant compliance costs.
- Technological obsolescence of existing products due to rapid advancements in diagnostics.
- Limited financial resources may hinder growth and expansion efforts.
- OTC Other tier listing indicates higher risk and lower liquidity.
What Are the Growth Opportunities for GWPC?
- Expanding OTC Product Line: Wholehealth Products, Inc. can capitalize on the growing demand for at-home diagnostic tests by expanding its OTC product line. The global OTC drugs market is projected to reach $220 billion by 2027. Introducing new diagnostic kits for common ailments and health monitoring can drive revenue growth and increase market share. Timeline: Launching 2-3 new OTC products per year.
- Strategic Partnerships with Retailers: Forming strategic partnerships with major retailers and pharmacies can significantly enhance the distribution and accessibility of Wholehealth Products' OTC diagnostic tests. Securing shelf space in national chains can drive sales volume and brand recognition. The retail pharmacy market is a key channel for reaching consumers seeking convenient healthcare solutions. Timeline: Establishing partnerships with 1-2 major retailers within the next 2 years.
- Penetrating the Point-of-Care Market: Expanding its presence in the point-of-care market by targeting medical clinics, physician offices, and hospitals can drive revenue growth. Offering diagnostic solutions that improve efficiency and patient outcomes can attract healthcare providers. The point-of-care diagnostics market is expected to grow as healthcare systems prioritize rapid and accurate testing. Timeline: Increasing sales to healthcare providers by 15% annually.
- Geographic Expansion within the U.S.: While currently focused on the U.S. market, Wholehealth Products, Inc. can explore opportunities for geographic expansion within the country. Targeting regions with high population density and unmet healthcare needs can drive revenue growth. Conducting market research to identify underserved areas and tailoring product offerings to local needs can be effective strategies. Timeline: Expanding sales operations to 2-3 new states within the next 3 years.
- Developing Innovative Diagnostic Technologies: Investing in research and development to develop innovative diagnostic technologies can provide a competitive edge and attract new customers. Focusing on areas such as rapid testing, personalized medicine, and digital health solutions can position Wholehealth Products, Inc. as a leader in the diagnostics market. The global diagnostics market is driven by technological advancements and the need for more accurate and efficient testing methods. Timeline: Launching 1-2 innovative diagnostic products within the next 5 years.
What Opportunities Does GWPC Have?
- Expanding product line to address unmet diagnostic needs.
- Strategic partnerships with retailers and healthcare providers.
- Geographic expansion within the U.S.
- Developing innovative diagnostic technologies.
What Threats Does GWPC Face?
- Intense competition from larger diagnostic companies.
- Evolving regulatory landscape for diagnostic tests.
- Technological obsolescence of existing products.
- Economic downturn impacting consumer spending on OTC products.
What Are GWPC's Competitive Advantages?
- Specialized focus on in vitro diagnostic tests for OTC and point-of-care markets.
- Established presence in the U.S. diagnostic testing market.
- Proprietary diagnostic test kit formulations and manufacturing processes.
What Does GWPC Do?
Incorporated in 2006 and based in Las Vegas, Nevada, Wholehealth Products, Inc. has evolved from Gulf Western Petroleum Corporation to a healthcare company specializing in in vitro diagnostic tests. This transformation, completed in July 2012, marked a strategic shift towards the development, manufacturing, and marketing of diagnostic solutions. The company targets both the over-the-counter (OTC) market, providing consumers with accessible diagnostic tools, and the point-of-care sector, serving healthcare professionals in medical clinics, physician offices, and hospitals. Their product range includes a variety of diagnostic test kits designed for ease of use and rapid results. Wholehealth Products operates primarily within the United States, focusing on delivering diagnostic solutions directly to consumers and healthcare providers. With a small team of four employees, the company navigates a competitive landscape, emphasizing innovation and market reach within its niche.
What Products and Services Does GWPC Offer?
- Develops in vitro diagnostic tests.
- Manufactures diagnostic test kits.
- Markets diagnostic tests for over-the-counter (OTC) use.
- Markets diagnostic tests for point-of-care use.
- Provides diagnostic solutions for consumers.
- Provides diagnostic solutions for healthcare professionals.
How Does GWPC Make Money?
- Develops and manufactures in vitro diagnostic tests.
- Sells diagnostic test kits directly to consumers through OTC channels.
- Sells diagnostic test kits to healthcare professionals for point-of-care use.
What Industry Does GWPC Operate In?
Wholehealth Products, Inc. operates within the medical specialties industry, a segment of the broader healthcare sector. This industry is characterized by rapid technological advancements, evolving regulatory landscapes, and increasing demand for point-of-care diagnostics. The market for in vitro diagnostic tests is projected to grow, driven by factors such as the aging population, rising prevalence of chronic diseases, and the shift towards personalized medicine. Competition includes established players like ALEAF, DGCRF, HHPHF, HRTT, and HTPRF, as well as smaller, specialized firms. Success in this industry requires continuous innovation, strategic partnerships, and effective market penetration.
Who Are GWPC's Key Customers?
- Individual consumers seeking over-the-counter diagnostic tests.
- Medical clinics using point-of-care diagnostic tests.
- Physician offices utilizing diagnostic tests for patient care.
- Hospitals employing diagnostic tests for various medical purposes.
Company Profile
Wholehealth Products, Inc. operates in the Medical - Specialties industry within the Healthcare sector. The company is led by CEO Charles A. Strongo BA, MBA. GWPC has traded publicly since 2005.
GWPC Valuation & Market Position
Relative to its peer group, GWPC's quantitative score of 46/100 is roughly in line with the peer average of 51/100.
GWPC Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative product offerings and market positioning.
- Increased social media mentions reflect growing interest and optimism among retail investors, often a precursor to upward momentum.
- The company's recent partnerships have been well-received, enhancing its credibility and expanding its reach in the wellness market.
Bear Case
- Concerns about market saturation in the wellness industry have emerged, leading some investors to question the company's long-term viability.
- Recent discussions indicate skepticism regarding the sustainability of revenue growth, with some analysts pointing to potential competitive pressures.
- Negative sentiment surrounding regulatory challenges could impact the company's operations and market perception in the near term.
- Some community members have expressed doubts about the effectiveness of the company's marketing strategies, suggesting a potential disconnect with target consumers.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
GWPC Latest News
No recent news available for GWPC.
GWPC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GWPC.
Price Targets
Wall Street price target analysis for GWPC.
GWPC MoonshotScore
What does this score mean?
The MoonshotScore rates GWPC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Charles A. Strongo BA, MBA
CEO
Charles A. Strongo serves as the CEO of Wholehealth Products, Inc. He holds a Bachelor of Arts (BA) and a Master of Business Administration (MBA). His background likely includes experience in business management, strategic planning, and financial oversight. With responsibility for managing a small team of four employees, Strongo's role encompasses a wide range of functions, from product development and marketing to sales and operations. His leadership is crucial for driving the company's growth and navigating the competitive healthcare market.
Track Record: Given the limited information available, it is difficult to assess Charles A. Strongo's specific track record at Wholehealth Products, Inc. However, as CEO, he has overseen the company's operations and strategic direction. Key achievements may include expanding the product line, securing partnerships, and increasing market share. His decisions regarding product development, marketing strategies, and financial management have likely influenced the company's performance and growth trajectory.
GWPC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Wholehealth Products, Inc. may not meet the minimum financial or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier often have limited regulatory oversight and may not be required to file regular financial reports with the SEC. This lack of transparency can make it more difficult for investors to assess the company's financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries a higher degree of risk due to the limited information available and the potential for fraud or manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited regulatory oversight and investor protection.
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal disputes involving the company.
- Company has been in operation since 2006.
- Focus on developing and manufacturing diagnostic tests.
- Serves both consumer and healthcare professional markets.
- Company changed its name to Wholehealth Products, Inc. in July 2012.
Wholehealth Products, Inc. Healthcare Stock: Key Questions Answered
What does Wholehealth Products, Inc. do?
Wholehealth Products, Inc. is a healthcare company that develops, manufactures, and markets in vitro diagnostic tests for over-the-counter (OTC) and point-of-care use in the United States. The company offers a range of diagnostic test kits for consumer use through OTC sales, as well as for healthcare professionals located at medical clinics, physician offices, and hospitals. Their focus is on providing accessible and convenient diagnostic solutions for both consumers and healthcare providers.
What are the main risks for GWPC?
The main risks for Wholehealth Products, Inc. include intense competition from larger diagnostic companies, the evolving regulatory landscape for diagnostic tests, and the potential for technological obsolescence of existing products. Additionally, the company's limited financial resources may hinder growth and expansion efforts. As an OTC Other stock, GWPC faces higher risks associated with limited financial disclosure, low trading volume, and potential price manipulation. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for GWPC?
Wholehealth Products, Inc. (GWPC) holds an AI score of 46/100 (low). Not financial advice.
How frequently does GWPC data refresh on this page?
GWPC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GWPC's recent stock price performance?
Wholehealth Products, Inc. (GWPC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on niche market of OTC and point-of-care diagnostic tests. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GWPC overvalued or undervalued right now?
Valuing Wholehealth Products, Inc. (GWPC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GWPC?
Before investing in Wholehealth Products, Inc. (GWPC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GWPC to a portfolio?
Key strength of Wholehealth Products, Inc. (GWPC): Focus on niche market of OTC and point-of-care diagnostic tests. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC Other tier listing and unknown disclosure status.
- AI analysis pending, limiting comprehensive insights.